Clifford is a Research Fellow at UniSA Clinical & Health Sciences.
He obtained a PhD in Biochemistry from Victoria University of Wellington after using gel-based proteomics to study the cellular effects of an algal toxin. His interests in proteomic technologies led the New Zealander to Denmark, where he spent time at the University of Southern Denmark and University of Copenhagen learning and implementing strategies to investigate the biological roles of protein post-translational modifications. These chemical additions are notoriously difficult to study because of their low abundance, which often require enrichment protocols and detection by high resolution mass spectrometry. Clifford also has extensive experience with liquid ... Read more
About me
Clifford is a Research Fellow at UniSA Clinical & Health Sciences.
He obtained a PhD in Biochemistry from Victoria University of Wellington after using gel-based proteomics to study the cellular effects of an algal toxin. His interests in proteomic technologies led the New Zealander to Denmark, where he spent time at the University of Southern Denmark and University of Copenhagen learning and implementing strategies to investigate the biological roles of protein post-translational modifications. These chemical additions are notoriously difficult to study because of their low abundance, which often require enrichment protocols and detection by high resolution mass spectrometry. Clifford also has extensive experience with liquid chromatography and Orbitrap mass spectrometers, as well as performing selected/parallel reaction monitoring for the quantification of peptides and metabolites.
Clifford joined the Future Industries Institute (UniSA STEM) in 2018 before moving to UniSA Clinical & Health Sciences in 2021. He is enthusiastic about scientific collaborations with research groups and industrial companies in South Australia. Interested parties are welcome to contact Clifford for initial discussions.
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2025 |
Open access
1
1
|
| 2024 |
Open access
|
| 2024 |
Open access
2
1
4
|
| 2024 |
Open access
3
2
2
|
| 2024 |
Open access
1
2
|
| 2024 |
2
|
| 2024 |
Open access
1
1
1
|
| 2023 |
Open access
1
1
21
|
| 2023 |
Open access
5
5
1
|
| 2023 |
Open access
25
22
4
|
| 2022 |
Open access
6
6
8
|
| 2022 |
Open access
18
18
8
|
| 2022 |
Open access
3
2
2
|
| 2022 |
Open access
8
8
5
|
| 2022 |
Open access
6
6
1
|
| 2021 |
Open access
29
1
|
| 2021 |
Open access
22
3
|
| 2021 |
Open access
16
14
3
|
| 2017 |
274
260
12
|
| 2017 |
13
13
8
|
| 2016 |
Open access
163
114
1
|
| 2015 |
Open access
48
47
2
|
| 2015 |
Open access
58
52
11
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Coopers Brewery | AUSTRALIA |
| Coopers Brewery Limited | AUSTRALIA |
| Csl Innovation Pty Ltd | AUSTRALIA |
| Evosep Biosystems | DENMARK |
| Leiden University | NETHERLANDS |
| Macquarie University | AUSTRALIA |
| Mahidol University | THAILAND |
| Monash University | AUSTRALIA |
| National Center for Genetic Engineering and Biotechnology | THAILAND |
| Norwegian University of Science and Technology | NORWAY |
| Novo Nordisk (Denmark) | DENMARK |
| Royal Adelaide Hospital | AUSTRALIA |
| The Queen Elizabeth Hospital | AUSTRALIA |
| The University of Notre Dame Australia | AUSTRALIA |
| University of Adelaide | AUSTRALIA |
| University of Copenhagen | DENMARK |
| University of Erlangen-Nuremberg | GERMANY |
| University of Melbourne | AUSTRALIA |
| University of Otago | NEW ZEALAND |
| University of Queensland | AUSTRALIA |
| University of Sains Malaysia | MALAYSIA |
| University of Science, Malaysia | MALAYSIA |
| University of South Australia | AUSTRALIA |
| University of Southern Denmark | DENMARK |
| University of Sydney | AUSTRALIA |
| University of Zurich | SWITZERLAND |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| 111153 - Mass Spectrometry assays for protein biomarker for the early detection of ovarian cancer | Current |
| Advancing Protein Therapeutic Development | Current |
| Functional Analysis and Quantification of Biopharmaceuticals in Tissues by Mass Spectrometry Imaging | Current |
| Mass spectrometry and spectroscopic analytical approaches for directed monoclonal antibody formulation development | Current |
| PAT Spectroscopic and MS techniques fornear/real-time product characterisation for plasma derived products | Current |
| Maximising yeast health during the industrial brewing process | Completed |
